Tag: Celgene
First Clinical Trial of STRO-001 Targeting CD74 to Treat Lymphoma and...
Researchers have begun dosing patients in its initial clinical trial of a new generation of precisely engineered - first-in-class - antibody-drug conjugate, or ADC,...
Sutro BioPharma and Celgene Refocus Immuno-Oncology Collaboration – Rapidly Advance Promising...
Earlier today Sutro Biopharma and Celgene confirmed that the companies decided to refocusing the 2014 immuno-oncology collaboration with on four programs that are advancing...
California Life Sciences Association Rewards Sutro Biopharma with Outstanding Partner Award
This week, during the California Life Sciences Association (CLSA) annual Pantheon Ceremony (DiNA Awards), Sutro Biopharma received the Outstanding Partner Award. By giving this award to Sutro, the...
Strategic Immuno-Oncology Collaboration Between Celgene and MedImmune Focuses on Non-Hodgkin’s Lymphoma,...
Celgene, headquartered in Summit, New Jersey, and MedImmune (Gaithersburg, Maryland), a wholly owned subsidiary of AstraZeneca, have entered into a strategic collaboration to develop and...
Sutro Biopharma and Celgene Expand Immuno-Oncology Product Discovery and Development Program
Sutro Biopharma, located in South San Francisco, and Celgene have entered into a strategic collaboration and option agreement designed to discover and develop multi-specific...
Dual-Warhead Takes Antibody Drug Conjugates a Step Further
Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing a cell-free protein synthesis technology, presented the first scientific data involving...
